23andMe to buy online pharmacy Lemonaid for $400M
The company plans to pair its direct-to-consumer genetic testing with Lemonaid’s online coaching and prescription delivery. It plans to buy the company for $400 million in stock and cash.
The company plans to pair its direct-to-consumer genetic testing with Lemonaid’s online coaching and prescription delivery. It plans to buy the company for $400 million in stock and cash.
Behind companies like Hims, Nurx and Lemonaid sits Truepill's technology, which handles the logistics, shipping and pharmacy fulfillment necessary to run the direct-to-consumer businesses.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.